GLP-1 for Hidradenitis Suppurativa: How Weight Loss Can Reduce Flares

Hidradenitis suppurativa (HS) is one of the most frustrating diseases I treat. The painful nodules, abscesses, and tunneling tracts that show up in the armpits, groin, and other skin folds can come and go for years. They often appear without an obvious trigger and despite excellent topical and antibiotic care. What patients are rarely told is how tightly HS is tied to body weight, metabolic syndrome, and the inflammatory state that comes with both. And how meaningfully that can change with the right intervention.

This article walks through what is known about the relationship between obesity and HS, why weight loss reduces flares for many patients, and how GLP-1 medications like semaglutide and tirzepatide fit into a modern HS care plan.

What Hidradenitis Suppurativa Is

HS is a chronic inflammatory skin disease, sometimes called acne inversa. It is a follicular disease at heart. The hair follicle becomes occluded, the trapped contents rupture into the surrounding tissue, and a neutrophilic inflammatory response follows. Over time that inflammation can scar, form sinus tracts, and leave patients with the tunneling lesions that define more advanced disease.

HS affects an estimated 0.1 to 1 percent of US adults based on modern claims-based studies. It often starts in the late teens or twenties, runs in families in many cases, and is significantly more common in women than men. It is also part of what dermatologists call the follicular occlusion tetrad alongside acne conglobata, dissecting cellulitis of the scalp, and pilonidal sinus, which is one reason it often shows up alongside other follicular disease.

There is no cure. The disease is highly treatable, and the goal of care has shifted in the last decade from "manage the flare" to "modify the disease."

Why Obesity and HS Are So Tightly Connected

If you have spent any time in HS support groups, you have probably seen the connection between body weight and HS come up. The clinical literature confirms it.

Obesity is the strongest modifiable risk factor for HS. Multiple large cohort studies have shown that higher body mass index is associated with:

• Greater HS disease severity
• More frequent flares
• More involved anatomic sites
• Slower response to topical, antibiotic, and biologic therapies
• Higher rates of metabolic syndrome, type 2 diabetes, and cardiovascular disease

Why is the link so tight? Several things appear to be happening at once.

Mechanical friction. Skin-on-skin friction in intertriginous folds is one of the proposed triggers for follicular rupture. Patients with more adipose tissue in the affected areas tend to have more friction and more occlusion.

Sweat and the local microbiome. Higher body weight is associated with more sweat trapping in folds, which can shift the skin's microbial environment and create a more inflammation-prone setting.

Systemic inflammation. Adipose tissue is not inert fat storage. It is an active endocrine organ that produces pro-inflammatory cytokines, including IL-6 and TNF-alpha. Those are the same cytokines that drive HS at a biological level. The more adipose tissue, the more inflammatory signal in circulation, and the more fuel for HS.

Insulin resistance. HS patients have higher rates of metabolic syndrome and insulin resistance than the general population. Insulin resistance worsens systemic inflammation and may itself contribute to follicular hyperkeratinization, the earliest step in HS pathogenesis.

What Weight Loss Does for HS

This is where the news gets better. Weight loss is one of the very few interventions that has shown consistent disease-modifying potential for HS.

Studies of HS patients who lose 5 to 15 percent or more of their body weight show:

• Reduced flare frequency
• Fewer new lesions per year
• Improved response to existing HS medications
• Reduced disease severity on validated severity scales like the IHS4

Importantly, the improvement is not all-or-nothing. Patients do not need to reach an ideal body weight to see benefit. Even modest, sustained reductions of 5 to 10 percent of body weight have been associated with meaningful clinical change. For a patient at 250 pounds, that is 12 to 25 pounds. That is achievable.

The catch is that achieving and maintaining that kind of weight loss with lifestyle changes alone is genuinely hard, especially for patients whose disease already includes pain, fatigue, and treatment burden. This is where modern weight management medications change the picture.

Where GLP-1 Medications Fit

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have transformed medical weight management. For HS patients in particular, two mechanisms are relevant.

Sustainable weight loss. GLP-1 medications produce average weight reductions of about 15 percent for semaglutide (STEP-1) and 20 to 22 percent for tirzepatide (SURMOUNT-1) when combined with lifestyle changes. That is in the range, and frequently beyond, where HS patients have historically seen meaningful disease improvement.

Direct anti-inflammatory effects. This is the part less often discussed. GLP-1 receptors are expressed on a range of immune cells, including monocytes, macrophages, T lymphocytes, and dendritic cells. Studies have shown that GLP-1 receptor activation reduces pro-inflammatory cytokine release, reduces C-reactive protein, and dampens activity in inflammatory pathways that overlap with those driving HS. The medication may be doing more than the weight loss alone.

This is something I see talked about more in the dermatology community every year. Multiple HS patients have been able to taper or discontinue their biologic after starting a GLP-1, which is not what anyone would have predicted a few years ago. The published literature is catching up to that clinical experience. A 2024 systematic review in JCMS supported the benefit of GLP-1 agonists in HS management, and I expect we will continue to see more evidence over the next two to three years. I have written more about this change in dermatology practice, including the recent JAMA Dermatology data, in GLP-1s and HS: the quiet shift in care.

It is important to be clear about what GLP-1 therapy is and is not.

It is not FDA-approved primary treatment for HS. Adalimumab was the first FDA-approved biologic for HS. Secukinumab is also now FDA-approved for HS, and bimekizumab is in late-stage HS development.

It is a clinically reasonable adjunct for HS patients who also meet weight management criteria. The decision is made by your clinician based on your overall medical picture, your current HS treatments, and your goals.

For a deeper look at how these medications work in the body, see our explainer on how GLP-1 medications work and what to expect in the first three months of GLP-1 therapy.

What an HS-Aware GLP-1 Program Should Do

If you are considering GLP-1 therapy as part of your HS care, a few things matter more than the medication itself.

Clinician review of your full picture. GLP-1 prescribing for an HS patient is not a checkbox exercise. Your clinician should know your HS severity, your current treatments (including biologics, antibiotics, and oral retinoids), your other medical history, and your goals. Medications like adalimumab or other immunomodulators do not prevent GLP-1 therapy, but the decision should be deliberate.

Coordination with your dermatologist. GLP-1 therapy is a weight management intervention, not a replacement for HS-specific care. If you are already on a biologic, antibiotic, or other systemic HS therapy, that should continue under your dermatologist's care while GLP-1 therapy supports the weight management goal.

Realistic expectations. Weight loss tends to be gradual, with the largest reductions occurring over the first 6 to 12 months. Most patients see flare improvement following sustained weight reduction, not immediately. The early weeks of GLP-1 therapy are about adjusting to the medication, not about flare control.

Ongoing clinical access. Side effects, dose adjustments, and questions are part of any GLP-1 journey. For HS patients especially, having a clinician available to discuss what is happening week to week is important.

Practical Considerations Before You Start

If you are thinking about GLP-1 therapy as part of your HS plan, here are the questions worth thinking through.

Are you already on a biologic for HS? GLP-1 therapy generally has a favorable interaction profile with biologics like adalimumab, secukinumab, and bimekizumab. Coordination with your dermatologist matters, but the combination is not unusual.

Are you on isotretinoin or oral antibiotics for HS? These do not prevent GLP-1 therapy, but your clinician should know.

Do you have type 2 diabetes or prediabetes? Many HS patients do. GLP-1 therapy can be especially well suited for this group, since the medication addresses both insulin resistance and weight at once.

What about surgery? If you have had wide local excision or have HS surgery planned, tell your clinician you are on a GLP-1. Lower body weight is generally associated with fewer wound-healing and surgical complications, although this has not been studied specifically for GLP-1 therapy in HS, so treat it as a reasonable expectation rather than a proven benefit. Separately, because GLP-1 medications slow gastric emptying, surgical and anesthesia teams increasingly ask patients to pause the medication before procedures that involve sedation, so coordinate the timing with them.

What the Evidence Does Not Yet Show

It is worth being honest about the limits of what we know. The bulk of the HS-and-weight-loss literature predates the modern GLP-1 era. Most studies of weight reduction in HS used bariatric surgery or intensive lifestyle intervention rather than pharmacologic weight loss. The biologic case for why GLP-1 therapy should help HS is strong, and clinical experience is accumulating, but large randomized trials of GLP-1 medications specifically for HS outcomes are still emerging.

That is not a reason to wait. Weight reduction is one of the few interventions with consistent disease-modifying potential for HS, and GLP-1 medications are the most effective pharmacologic tool we have to achieve it. The combination is clinically reasonable. It just is not, and may never be, FDA-approved as an HS therapy specifically.

Bottom Line

If you live with hidradenitis suppurativa and your body weight is a contributor to your disease, GLP-1 therapy is worth a conversation with your clinician. The relationship between obesity, systemic inflammation, and HS is well established. Meaningful weight loss reduces flare frequency and severity for many patients. GLP-1 medications are the most effective pharmacologic tool currently available to help you get there, and they may be doing additional anti-inflammatory work beyond the weight loss itself.

A clinician should evaluate your full medical history, your current HS care, and your goals to determine whether GLP-1 therapy is appropriate. Good care includes clinician oversight, ongoing monitoring, and clinical support so the treatment supports your skin, not just the scale.

Frequently Asked Questions

Is GLP-1 therapy FDA-approved for HS? No. GLP-1 medications like semaglutide and tirzepatide are FDA-approved for weight management, not as primary treatment for HS. They are used in HS patients as an adjunct to address the weight and metabolic contributors to disease severity.

How much weight do I need to lose to see HS improvement? The medical literature suggests that 5 to 15 percent of body weight is associated with meaningful HS improvement for many patients. Results vary, and improvement tends to follow sustained weight reduction rather than rapid early weight loss.

Can I take a GLP-1 medication while on adalimumab or another HS biologic? For most patients, yes. GLP-1 therapy and HS biologics have a generally favorable interaction profile, but the decision is individualized. Your clinician will review your full medication list before prescribing.

Will GLP-1 therapy replace my current HS treatments? No. GLP-1 therapy supports weight management. It does not replace the topicals, antibiotics, biologics, or surgical care your dermatologist may be providing for your HS. Those continue alongside the weight management intervention.

How fast will I see a difference in my HS flares? HS improvement tends to follow weight reduction, which is gradual. Most patients see meaningful weight loss over the first 6 to 12 months of GLP-1 therapy, with flare changes following that timeline. The early weeks are about adjusting to the medication, not about flare control.

Related Reading

• How GLP-1 Medications Work. A clinician's breakdown of how semaglutide and tirzepatide actually work.
• The First 3 Months on a GLP-1. What to expect, side effects, and pace of change.
• The Gila Monster Behind Modern Weight Loss. The unlikely scientific story behind GLP-1 medications.
• Eczema vs. Psoriasis. Distinguishing inflammatory skin diseases. Useful background if you are unsure whether your skin condition is HS or something else.

Sources

• Sartorius K, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211-213.
• Kromann CB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94(5):553-557.
• Sivanand A, et al. Weight loss and hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2020;24(1):64-72.
• Garg A, et al. Comorbidity of hidradenitis suppurativa: a review of the literature. Br J Dermatol. 2018;179(5):1006-1013.
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.